Hepatitis C Testing, Monitoring, and Linkage to Care Practices among a Large Underserved and Ethnically Diverse Birth Cohort

2017 ◽  
Vol 152 (5) ◽  
pp. S1164
Author(s):  
Nicole Kim ◽  
Catherine Magee ◽  
Mandana Khalili
2019 ◽  
Vol 10 ◽  
pp. 215013271988429 ◽  
Author(s):  
Allison M. Cole ◽  
Gina A. Keppel ◽  
Laura-Mae Baldwin ◽  
Ryan Gilles ◽  
John Holmes ◽  
...  

Introduction: An estimated 2.4 million people in the United States live with hepatitis C. Though there are effective treatments for chronic hepatitis C, many infected individuals remain untreated because 40% to 50% of individuals with chronic hepatitis C are unaware of their hepatitis C status. In 2013, the United States Preventive Services Task Force (USPSTF) recommended that adults born between 1945 and 1965 should be offered one-time hepatitis C screening. The purpose of this study is to describe rates of birth cohort hepatitis C screening across primary care practices in the WWAMI region Practice and Research Network (WPRN). Methods: Cross-sectional observational study of adult patients born between 1945 and 1965 who also had a primary care visit at 1 of 9 participating health systems (22 primary care clinics) between July 31, 2013 and September 30, 2015. Data extracted from the electronic health record systems at each clinic were used to calculate the proportion of birth cohort eligible patients with evidence of hepatitis C screening as well as proportions of screened patients with positive hepatitis C screening test results. Results: Of the 32 139 eligible patients, only 10.9% had evidence of hepatitis C screening in the electronic health record data (range 1.2%-49.1% across organizations). Among the 4 WPRN sites that were able to report data by race and ethnicity, the rate of hepatitis C screening was higher among African Americans (39.9%) and American Indians/Alaska Natives (23.2%) compared with Caucasians (10.7%; P < .001). Discussion: Rates of birth cohort hepatitis C screening are low in primary care practices. Future research to develop and test interventions to increase rates of birth cohort hepatitis C screening in primary care settings are needed.


2016 ◽  
Vol 131 (2_suppl) ◽  
pp. 12-19 ◽  
Author(s):  
Rajiv C. Patel ◽  
Claudia Vellozzi ◽  
Bryce D. Smith

Pathogens ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 1570
Author(s):  
David Petroff ◽  
Olaf Bätz ◽  
Katrin Jedrysiak ◽  
Anja Lüllau ◽  
Jan Kramer ◽  
...  

(1) Background: Low rates of hepatitis C virus (HCV) diagnosis and sub-optimal linkage to care constitute barriers toward eliminating the infection. In 2012/2013, we showed that HCV screening in primary care detects unknown cases. However, hepatitis C patients may not receive further diagnostics and therapy because they drop out during the referral pathway to secondary care. Thus, we used an existing network of primary care physicians and a practice of gastroenterology to investigate the pathway from screening to therapy. (2) Methods: HCV screening was prospectively included in a routine check-up of primary care physicians who cooperated regularly with a private gastroenterology practice. Anti-HCV-positive patients were referred for further specialized diagnostics and treatment if indicated. (3) Results: Seventeen primary care practices screened 1875 patients. Twelve individuals were anti-HCV-positive (0.6%), six of them reported previous antiviral HCV therapy, and one untreated patient was HCV-RNA-positive (0.05% of the population). None of the 12 anti-HCV-positive cases showed up at the private gastroenterology practice. Further clinical details of the pathway from screening to therapy could not be analyzed. (4) Conclusions: The linkage between primary and secondary care appears to be problematic in the HCV setting even among cooperating partners, but robust conclusions require larger datasets.


2016 ◽  
Vol 131 (2_suppl) ◽  
pp. 84-90 ◽  
Author(s):  
Lesley S. Miller ◽  
Francois Rollin ◽  
Shelly-Ann Fluker ◽  
Kristina L. Lundberg ◽  
Brandi Park ◽  
...  

2020 ◽  
Vol 3 (1) ◽  
pp. 3-14
Author(s):  
Sophie E Cousineau ◽  
Aysegul Erman ◽  
Lewis Liu ◽  
Sahar Saeed ◽  
Lorraine Fradette ◽  
...  

2014 ◽  
Vol 104 (6) ◽  
pp. e69-e74 ◽  
Author(s):  
Sarah Larney ◽  
Madeline K. Mahowald ◽  
Nicholas Scharff ◽  
Timothy P. Flanigan ◽  
Curt G. Beckwith ◽  
...  

Author(s):  
Pablo Ryan ◽  
Jorge Valencia ◽  
Guillermo Cuevas ◽  
Juan Torres-Macho ◽  
Jesús Troya ◽  
...  

Author(s):  
Christina Greenaway ◽  
Iuliia Makarenko ◽  
Claire Abou Chakra ◽  
Balqis Alabdulkarim ◽  
Robin Christensen ◽  
...  

Chronic hepatitis C (HCV) is a public health priority in the European Union/European Economic Area (EU/EEA) and is a leading cause of chronic liver disease and liver cancer. Migrants account for a disproportionate number of HCV cases in the EU/EEA (mean 14% of cases and >50% of cases in some countries). We conducted two systematic reviews (SR) to estimate the effectiveness and cost-effectiveness of HCV screening for migrants living in the EU/EEA. We found that screening tests for HCV are highly sensitive and specific. Clinical trials report direct acting antiviral (DAA) therapies are well-tolerated in a wide range of populations and cure almost all cases (>95%) and lead to an 85% lower risk of developing hepatocellular carcinoma and an 80% lower risk of all-cause mortality. At 2015 costs, DAA based regimens were only moderately cost-effective and as a result less than 30% of people with HCV had been screened and less 5% of all HCV cases had been treated in the EU/EEA in 2015. Migrants face additional barriers in linkage to care and treatment due to several patient, practitioner, and health system barriers. Although decreasing HCV costs have made treatment more accessible in the EU/EEA, HCV elimination will only be possible in the region if health systems include and treat migrants for HCV.


Sign in / Sign up

Export Citation Format

Share Document